Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys

International Journal of Cancer

Volumn 81, Issue 1, 1999, Pages 148-155

  Kreitman, Robert J ^a   Wang, Qing Cheng ^a   FitzGerald, David J P ^a   Pastan, Ira ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD22 ANTIGEN; CYSTEINE; DIFFERENTIATION ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOTOXIN; PSEUDOMONAS EXOTOXIN; RECOMBINANT ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; ANTIBODY STRUCTURE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CELL DESTRUCTION; CANCER REGRESSION; CONTROLLED STUDY; DISULFIDE BOND; DOSE RESPONSE; ESCHERICHIA COLI; LETHAL DOSE; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; TUMOR XENOGRAFT;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BACTERIAL TOXINS; BURKITT LYMPHOMA; CELL ADHESION MOLECULES; EXOTOXINS; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTOXINS; LECTINS; LYMPHOMA, B-CELL; MACACA FASCICULARIS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; TRANSPLANTATION, HETEROLOGOUS; VIRULENCE FACTORS;

EID: 0033047767     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990331)81:1<148::AID-IJC24>3.0.CO;2-L     Document Type: Article

References (34)

1. ALLURED, V.S., COLLIER, R.J., CARROLL, S.F. and MCKAY, D.B., Structure of exotoxin A of Pseudomonas aeruginosa at 3.0 angstrom resolution. Proc. nat. Acad. Sci. (Wash.), 83, 1320-1324 (1986).
2. AMLOT, P.L. and 13 OTHERS. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 82, 2624-2633 (1993).
3. BENHAR, I. and PASTAN, I., Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice. Clin. Cancer Rex., 1, 1023-1029 (1995).
4. BENHAR, I., REITER, Y, PAI, L.H. and PASTAN, I., Administration of disultide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice. Int. J. Cancer, 62, 351-355 (1995).
5. BOLOGNESI, A., TAZZARI, P.L., OLIVTERI, F., POLITO, L., LEMOLI, R., TERENZI, A., PASQUALUCCI, L., FALINI, B. and STIRPE, F., Evaluation of immunoloxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies. Brit. J. Haematol., 101, 179-188 (1998).
6. CHIRON, M.F., FRYLING, C.M. and FITZGERALD, D.J., Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J. biol. Chem., 269, 18167-18176 (1994).
7. CLARK, E.A., CD22, a B cell-specific receptor, mediates adhesion and signal transduction. J. Immunol., 150, 4715-4718 (1993).
8. ENGERT, A. and 14 OTHERS, A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood. 89, 403-410 (1997).
9. ENGERT, A., MARTIN, G., AMLOT, P., WIJDENES, J., DIEHL, V. and THORPE, P., Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice. Int. J. Cancer, 49, 450-456 (1991).
10. GHETIE, M.-A., RICHARDSON, J., TUCKER, T., JONES, D., UHR, J.W. and VITETTA, E.S., Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Res., 51, 5876-5880 (1991).
11. HESSLER, J.L. and KREITMAN, R.J., An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry, 36, 14577-14582 (1997).
12. HORSSEN, P.J.V., PREIJERS, F.W.M.B., OOSTERHOUT, Y.V.J.M.V. and WITTE, T.D., Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice. Int. J. Cancer, 68, 378-383 (1996).
13. KOUNNAS, M.Z., MORRIS, R.E., THOMPSON, M.R., FITZGERALD, D.J., STRICKLAND, D.K. and SAELINGER, C.B., The α2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J. biol. Chem., 267, 12420-12423 (1992).
14. KREITMAN, R.J., BAILON, P., CHAUDHARY, V.K., FITZGERALD, D.J.P. and PASTAN, I., Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukm-2 receptor-expressing human carcinoma. Blood, 83, 426-434 (1994).
15. KREITMAN, R.J., HANSEN, H.J., JONES, A.L., FITZGERALD, D.J.P., GOLDENBERG, D.M. and PASTAN, I., Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Res., 53, 819-825 (1993).
16. 4E, a recombinant fusion of interleukin 6 with Pseudomonas exotoxin. Bioconjugate Chem., 4, 581-585 (1993).
17. KREITMAN, R.J. and PASTAN, I., Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem. J., 307, 29-37 (1995).
18. KREITMAN, R.J. and PASTAN, I., Accumulation of a recombinant immunotoxin in vivo: less than 1,000 molecules per cell is sufficient for complete responses. Cancer Res., 58, 968-975 (1998).
19. Y damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. Clin. Cancer Res., 1, 1589-1594 (1995).
20. MANSFIELD, E., AMLOT, P., PASTAN, I. and FITZGERALD, D.J., Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood, 90, 2020-2026 (1997a).
21. MANSFIELD, E., CHIRON, M.F., AMLOT, P., PASTAS, I. and FITZGERALD, D.J., Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells. Biochem. Soc. Trans., 25, 709-714 (1997b).
22. MANSFIELD, E., PASTAN, I. and FITZGERALD, D.J., Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies. Bioconjugate Chem., 7, 557-563 (1996).
23. 280 generates the enzymatically active fragment which translocates to the cytosol. J. biol. Chem., 267, 25396-25401 (1992).
24. REITER, Y., WRIGHT, A.F., TONGE, D.W. and PASTAN, I., Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice. Int. J. Cancer, 67, 113-123 (1996).
25. ROZEMULLER, H., ROMBOUTS, W.J.C., TOUW, I.P., FITZGERALD, D.J.P., KREITMAN, R.J., PASTAN, I., HAGENBEEK, A. and MARTENS, A.C.M., Treatment of acute myelocytic leukemia with interleukin-6 Pseudomonas exotoxin fusion protein in a rat leukemia model. Leukemia, 10, 1796-1803 (1996).
26. SAUSVILLE, E.A. and 14 OTHERS, Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood, 85, 3457-3465 (1995).
27. SENDEROWICZ, A.M., VITETTA, E., HEADLEE, D., GHETIE, V., UHR, J.W., FIGG, W.D., LUSH, R.M., STETLER-STEVENSON, M., KERSHAW. G., KINGMA, D.W., JAFFE, E.S. and SAUSVILLE, E.A., Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunntoxin. Ann. intern. Med., 126, 882-885 (1997).
28. SIEGALL, C.B., CHAUDHARY, V.K., FITZGERALD, D.J. and PASTAN, I., Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J. biol. Chem., 264, 14256-14261 (1989).
29. SIEGALL, C.B., LIGGITT, D., CHARGE, D., MIXAN, B., SUGAI, J., DAVIDSON, T. and STEINITZ, M., Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. Clin. Cancer Res., 3, 339-345 (1997).
30. SOLER-RODRIGUEZ, A.-M., GHETIE, M.-A., OPPENHEIMER-MARKS, N., UHR, J.W. and VITETTA, E.S., Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp. Cell Res., 206, 227-234 (1993).
31. THEUER, C., KASTURI, S. and PASIAN, I., Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes. Biochemistry. 33, 5894-5900 (1994).
32. THEUER, C.P., BUCHNER, J., FITZGERALD, D. and PASTAN, I., The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion. Proc. nat. Acad. Sci. (Wash.), 90, 7774-7778 (1993).
33. VITETTA, E.S. and 12 OTHERS, Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res., 51, 4052-1058 (1991).
34. WINKLER. U., GOTTSTEIN, C., SCHON, G., KAPP, U., WOLF, J., HANSMANN, M.-L., BOHLEN, H., THORPE, P., DIEHL, V. and ENGERT, A., Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunoloxins. Blood, 83, 466-475 (1994).